Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

• Corporate Author: SpringerLink (Online service)
• Other Authors: Yarden, Yosef (Editor, http://id.loc.gov/vocabulary/relators/edt), Elkabets, Moshe (Editor, http://id.loc.gov/vocabulary/relators/edt)
• Format: Electronic eBook
• Language: English
• Published: Cham : Springer International Publishing : Imprint: Springer, 2018.
• Edition: 1st ed. 2018.
• Series: Resistance to Targeted Anti-Cancer Therapeutics, 15
• Subjects: Cancer research.; Cancer Research.
• Physical Description: XX, 242 p. 22 illus. in color. online resource.
• ISBN: 9783319679327
• ISSN: 2196-5501 ;
• DOI: 10.1007/978-3-319-67932-7

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.